Hysingla ER is ready for the marketplace, just two months after FDA approval.
CEO Ian Read told investors the company has cash to make a deal, but there is no urgent need.
Biogen Idec handed out 250 Fitbits last year to better understand how MS affects patients' mobility, and how its medications hinder disease progression.
AstraZeneca's Nexium now has generic competition, toxicity worries researchers about new cancer approaches and a former Pfizer exec will now lead an e-cigarette company.
The FDA approved NPS Pharmaceuticals's rare-disease drug Friday. The company, which Shire shelled out $5.2 billion to buy, expects it to hit the market during the second-quarter.
The drugmakers have filed alirocumab with the FDA, closing the gap between its candidate and Amgen's evolucumab.
FDA has approved Novartis's Bexsero after approving Pfizer's Trumemba this past October.
Two new classes of medicines have shown unparalleled efficacy in oncology, but there are growing concerns about the treatments' safety.
Actavis acquires Auden Mckenzie for $459 million; Sanofi/Regeneron's PCSK9 inhibitor could be first to market; Gilead strikes a deal for Harvoni and Sovaldi with four German health insurers.
Brent Saunders, the mind behind the $66 billion acquisition of Allergan, which elevated Actavis to the tenth-largest drugmaker in the world, tells Forbes that growth through acquisition is not simply a short-term tactic but part of a long-term strategy.
Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.